Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Ovarian Neoplasms 2Vaccinia 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

ribociclib 2palbociclib 2Gonadotropin-Releasing Hormone 2Doxorubicin 2Docetaxel 2Anastrozole 2AZD9833 2trastuzumab deruxtecan 1taxane 1pertuzumab 1pegfilgrastim 1ipatasertib 1atezolizumab 1abemaciclib 1Trastuzumab 1Sodium Chloride 1Paclitaxel 1Letrozole 1Ibuprofen 1Fulvestrant 1Drug Therapy 1Denosumab 1Cyclophosphamide 1Codeine 1Capecitabine 1Botulinum Toxins, Type A 1Bevacizumab 1Acetaminophen 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Diseases × taxane × Clear all
NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡